FIA
PSTX

FNY Investment Advisers’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

FNY Investment Advisers’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,200
Closed -$11K – 1062
2024
Q4 		$11K Buy
+1,200
New +$6.26K 0.01% 486
2024
Q1 		– Sell
-8,250
Closed -$27K – 875
2023
Q4 		$27K Buy
8,250
+750
+10% +$1.93K 0.03% 243
2023
Q3 		$17K Sell
7,500
-4,000
-35% -$8.38K 0.01% 327
2023
Q2 		$20K Buy
11,500
+1,500
+15% +$3.83K 0.03% 247
2023
Q1 		$30K Buy
+10,000
New +$59.9K 0.03% 227

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

FNY Investment Advisers's PSTX Position: Q1 2025 in Review

FNY Investment Advisers sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 1,200 shares — an estimated $11K sold.

FNY Investment Advisers first reported a position in PSTX in Q1 2023 and held it in 5 quarters. The position peaked at $30K in Q1 2023. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • FNY Investment Advisers reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 1,200 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $11K.
  • FNY Investment Advisers first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2023 and held it in 5 quarters.
  • FNY Investment Advisers's Poseida Therapeutics, Inc. Common Stock position peaked at $30K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on FNY Investment Advisers's 13F filing for Q1 2025, filed 17 Apr 2025.